A Canadian Perspective on Perioperative Systemic Therapy in Resectable Non-Small Cell Lung Cancer.

Curr Oncol · 2025 · PMC12840373 · PMID 41590340

Europe PMC DOI

hedged sentence

0.0620

closest p · 1.2× alpha

0.0620

boldest claim

The sentences

showed a trendp = 0.062so close (0.05 < p ≤ 0.1)

The final updated 9-year follow-up showed a trend toward improved OS (HR = 0.80; 90% CI, 0.63–1.02; p = 0.062, one-tailed) and a 7% advantage in 8-year OS favoring adjuvant carboplatin-paclitaxel (51% vs. 44%; p = 0.087) [ 12 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.